Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Total Debt (2016 - 2025)

Abeona Therapeutics (ABEO) has 11 years of Total Debt data on record, last reported at $19.8 million in Q3 2025.

  • For Q3 2025, Total Debt rose 5.9% year-over-year to $19.8 million; the TTM value through Sep 2025 reached $19.8 million, up 5.9%, while the annual FY2024 figure was $19.0 million, N/A changed from the prior year.
  • Total Debt reached $19.8 million in Q3 2025 per ABEO's latest filing, up from $19.6 million in the prior quarter.
  • Across five years, Total Debt topped out at $34.4 million in Q2 2021 and bottomed at $4.2 million in Q4 2022.
  • Average Total Debt over 4 years is $17.9 million, with a median of $18.6 million recorded in 2024.
  • Peak YoY movement for Total Debt: skyrocketed 1513.2% in 2021, then plummeted 74.73% in 2022.
  • A 4-year view of Total Debt shows it stood at $8.4 million in 2021, then plummeted by 50.6% to $4.2 million in 2022, then surged by 355.51% to $19.0 million in 2024, then increased by 4.16% to $19.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Debt were $19.8 million in Q3 2025, $19.6 million in Q2 2025, and $19.3 million in Q1 2025.